This is an unofficial archive of PsychonautWiki as of 2025-08-11T15:14:44Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.
DOI: Difference between revisions
>Josikins m Text replacement - "*'''Effect::Salivation'''" to "*'''Effect::Increased salivation''' " |
>Larnaca |
||
| (42 intermediate revisions by 13 users not shown) | |||
| Line 2: | Line 2: | ||
{{SubstanceBox/DOI}} | {{SubstanceBox/DOI}} | ||
'''2,5-Dimethoxy-4-iodoamphetamine''' (also known as '''DOI''') is a lesser-known [[Psychoactive class::psychedelic]] substance of the [[chemical class:: | '''2,5-Dimethoxy-4-iodoamphetamine''' (also known as '''DOI''') is a lesser-known [[Psychoactive class::psychedelic]] substance of the [[chemical class::Substituted amphetamines|amphetamine]] class. It is a member of the [[DOx]] family of psychedelic amphetamines. | ||
The synthesis of DOI was first | The synthesis of DOI was first described in 1972<ref name="Coutts1973">{{cite journal|last1=Coutts|first1=R. T.|last2=Malicky|first2=J. L.|year=1973|title=The Synthesis of Some Analogs of the Hallucinogen 1-(2,5-Dimethoxy-4-methylphenyl)-2-aminopropane (DOM)|journal=Canadian Journal of Chemistry|volume=51|issue=9|pages=1402-1409|doi=10.1139/v73-210|issn=0008-4042|eissn=1480-3291|oclc=02248672}}</ref><ref name="Zamberlan2018">{{cite journal|title=The Varieties of the Psychedelic Experience: A Preliminary Study of the Association Between the Reported Subjective Effects and the Binding Affinity Profiles of Substituted Phenethylamines and Tryptamines|year=2018|doi-access=free|first1=F.|last1=Zamberlan|first2=C.|last2=Sanz|first3=R. M.|last3=Vivot|first4=C.|last4=Pallavicini|first5=F.|last5=Erowid|first6=E.|last6=Erowid|first7=E.|last7=Tagliazucchi|pmc=6235949|pmid=30467466|doi=10.3389/fnint.2018.00054|volume=12|issue=54|journal=Frontiers in Integrative Neuroscience|eissn=1662-5145|oclc=1132048937}}</ref> and its usage in humans was first documented by [[Alexander Shulgin]] in the 1991 book [[PiHKAL]] ("Phenethylamines I Have Known and Loved").{{citation needed}} DOI is very well-researched compared to most psychedelics. It is regularly used in research as a radioligand to map [[Serotonin#The 5-HT System|serotonin-2A]] [[receptors]] in the brain.{{citation needed}} | ||
DOI | The effects of DOI are often compared to those of [[LSD]], although notable differences can be distinguished. Besides the significantly longer duration, the experience is commonly reported to be more [[stimulating]] than LSD, with a more pronounced [[body load]] and a less complex head space. The after effects include long-lasting residual stimulation and [[wakefulness|difficulty sleeping]], which, depending on the dose and time taken during the day, may persist for days afterwards. | ||
DOI is sometimes sold as a substitute for LSD, or even sold falsely as LSD. This can be dangerous because DOI does not have the same established safety profile as LSD.<ref>{{cite web|title=LSD Blotter Acid Mimics (Actually Containing 4-Iodo-2,5-dimethoxyamphetamine (DOI) And 4-Chloro-2,5-dimethoxyamphetamine (DOC)) In Lantana, Florida|archive-url=http://web.archive.org/web/20090204025435/http://www.usdoj.gov/dea/programs/forensicsci/microgram/mg0608/mg0608.html|url=http://www.usdoj.gov/dea/programs/forensicsci/microgram/mg0608/mg0608.html|archive-date=February 4, 2009|work=Microgram Bulletin|publisher=Drug Enforcement Administration (DEA)|date=June 2008|oclc=54464390}}</ref> | |||
Along with its sensitive dose-response and unusually long duration, many reports also suggest that this substance may be overly difficult to use safely for those who are not already experienced with [[psychedelics]]. Therefore it is highly advised to approach this highly dose-sensitive, and long-lasting [[psychedelic]] substance with the proper amount of precaution and [[harm reduction practices]] if using it. | |||
==History and culture== | ==History and culture== | ||
{{historyStub}} | {{historyStub}} | ||
DOI was first synthesized by a team at the University of Alberta in 1972.<ref> | DOI was first synthesized by a team at the University of Alberta in 1972.<ref name="Coutts1973"/><ref name="Zamberlan2018"/> | ||
==Chemistry== | ==Chemistry== | ||
DOI, or 2,5-Dimethoxy-4-iodoamphetamine, is a molecule of the [[amphetamine]] class. Amphetamines are substituted [[phenethylamines]] containing a phenyl ring bound to an amino (NH<sub>2</sub>) group through an ethyl chain and a methyl group bound to the alpha carbon R<sub>α</sub>. DOI contains methoxy functional groups OCH<sub>3</sub> attached to carbons R<sub>2</sub> and R<sub>5</sub> as well as an iodine atom attached to carbon R<sub>4</sub> of the phenyl ring. DOI is the amphetamine, or alpha-methylated analogue, of the phenethylamine [[2C-I]].<ref> | DOI, or 2,5-Dimethoxy-4-iodoamphetamine, is a molecule of the [[Substituted amphetamines|amphetamine]] class. Amphetamines are substituted [[phenethylamines]] containing a phenyl ring bound to an amino (NH<sub>2</sub>) group through an ethyl chain and a methyl group bound to the alpha carbon R<sub>α</sub>. DOI contains methoxy functional groups OCH<sub>3</sub> attached to carbons R<sub>2</sub> and R<sub>5</sub> as well as an iodine atom attached to carbon R<sub>4</sub> of the phenyl ring. DOI is the amphetamine, or alpha-methylated analogue, of the phenethylamine [[2C-I]].<ref name="PiHKAL">{{cite book|title=PiHKAL: A Chemical Love Story|title-link=PiHKAL|author-link1=Alexander Shulgin|author1=Alexander Shulgin|author2=Ann Shulgin|year=1991|publisher=Transform Press|location=United States|isbn=0963009605|oclc=1166889264|chapter-url=https://erowid.org/library/books_online/pihkal/pihkal067.shtml|chapter=#67. DOI}}</ref> | ||
==Pharmacology== | ==Pharmacology== | ||
{{Further|Serotonergic psychedelic}} | {{Further|Serotonergic psychedelic}} | ||
DOI's [[psychedelic]] effects are believed to come from its efficacy as an [[agonist]] at the [[Serotonin#The 5-HT System|5-HT<sub>2A</sub>]], [[Serotonin#The 5-HT System|5-HT<sub>2B</sub>]] and [[Serotonin#The 5-HT System|5-HT<sub>2C</sub>]] [[receptor]]s.<ref name="head twitch">Head-twitch response in rodents induced by the hallucinogen 2,5-dimethoxy-4-iodoamphetamine: a comprehensive history, a re-evaluation of mechanisms, and its utility as a model | DOI's [[psychedelic]] effects are believed to come from its efficacy as an [[agonist]] at the [[Serotonin#The 5-HT System|5-HT<sub>2A</sub>]], [[Serotonin#The 5-HT System|5-HT<sub>2B</sub>]] and [[Serotonin#The 5-HT System|5-HT<sub>2C</sub>]] [[receptor]]s.<ref name="head twitch">{{cite journal|title=Head-twitch response in rodents induced by the hallucinogen 2,5-dimethoxy-4-iodoamphetamine: a comprehensive history, a re-evaluation of mechanisms, and its utility as a model|pmid=22517680|pmc=3722587|doi=10.1002/dta.1333|first1=C. E.|last1=Canal|first2=D.|last2=Morgan|year=2012|volume=4|issue=7-8|pages=556-576|issn=1942-7603|eissn=1942-7611|oclc=231680670|journal=Drug Testing and Analysis}}</ref> However, the role of these interactions and how they result in the [[psychedelic]] experience continues to remain the subject of ongoing scientific inquiry. | ||
DOI | Besides its action as a [[psychedelic]], DOI has been shown to be an extremely potent inhibitor of tumour necrosis factor-alpha inflammation at picomolar concentrations in cell studies. TNF-alpha is an important target for research into degenerative conditions such as rheumatoid arthritis and Alzheimer's disease where the disease process involves tissue damage through chronic inflammation. This could make DOI and other 5-HT<sub>2A</sub> agonists an entirely new area for development of novel treatments for these conditions.<ref>{{cite journal|title=Serotonin 5-Hydroxytryptamine<sub>2A</sub> Receptor Activation Suppresses Tumor Necrosis Factor-α-Induced Inflammation with Extraordinary Potency|pmid=18708586|doi=10.1124/jpet.108.143461|first1=B.|last1=Yu|first2=J.|last2=Becnel|first3=M.|last3=Zerfaoui|first4=R.|last4=Rohatgi|first5=A. H.|last5=Boulares|first6=C. D.|last6=Nichols|journal=Journal of Pharmacology and Experimental Therapeutics|year=2008|volume=327|issue=2|pages=316-323|issn=0022-3565|eissn=1521-0103|oclc=1606914}}</ref> | ||
| | |||
| | |||
| | |||
| | |||
|- | |||
| | |||
DOI has also been shown to induce rapid growth and reorganization of dendritic spines and synaptic connections with other [[neurons]], processes known to underlie neuroplasticity.<ref>{{cite journal|last1=Jones|first1=K. A.|last2=Srivastava|first2=D. P.|last3=Allen|first3=J. A.|last4=Strachan|first4=R. T.|last5=Roth|first5=B. L.|last6=Penzes|first6=P.|year=2009|title=Rapid modulation of spine morphology by the 5-HT<sub>2A</sub> serotonin receptor through kalirin-7 signaling|journal=Proceedings of the National Academy of Sciences|volume=106|issue=46|pages=19575-19580|pmid=19889983|doi=10.1073/pnas.0905884106|pmc=2780750|issn=0027-8424|eissn=1091-6490|oclc=43473694|doi-access=free}}</ref> | |||
DOI | A study demonstrated that DOI, [[DMT]], [[LSD]], and noribogaine (a metabolite of [[ibogaine]]) promote neuritogenesis both ''in vitro'' and ''in vivo''.<ref>{{cite journal|title=Psychedelics Promote Structural and Functional Neural Plasticity|first1=C.|last1=Ly|first2=A. C.|last2=Greb|first3=L. P.|last3=Cameron|first4=J. M.|last4=Wong|first5=E. V.|last5=Barragan|first6=P. C.|last6=Wilson|first7=K. F.|last7=Burbach|first8=S. S.|last8=Zarandi|first9=A.|last9=Sood|first10=M. R.|last10=Paddy|first11=W. C.|last11=Duim|first12=M. Y.|last12=Dennis|first13=A. K.|last13=McAllister |first14=K. M.|last14=Ori-McKenney|first15=J. A.|last15=Gray|first16=D. E.|last16=Olson|year=2018|volume=23|issue=11|pages=3170-3182|doi=10.1016/j.celrep.2018.05.022|pmc=6082376|pmid=29898390|doi-access=free|issn=2211-1247|journal=Cell Reports}}</ref> | ||
==Subjective effects== | ==Subjective effects== | ||
| Line 64: | Line 35: | ||
|{{effects/physical| | |{{effects/physical| | ||
*'''[[Effect::Stimulation]]''' - In terms of its effects on the physical energy levels of the user, DOI is usually considered to be extremely stimulating at levels which are capable of | *'''[[Effect::Stimulation]]''' - In terms of its effects on the physical energy levels of the user, DOI is usually considered to be extremely stimulating at levels which are capable of becoming uncomfortable and overwhelming. This can result in a shakiness and unsteadiness of the hands but encouraging one to move around, run, dance, climb and generally engage in physical activities. In comparison, other more commonly used psychedelics such as [[psilocin]] are generally sedating and relaxed. | ||
*'''[[Effect::Spontaneous physical sensations]]''' - The "body high" of DOI often described as being notably more intense in comparison to most classical psychedelics such as [[LSD]]. The sensation itself can be described as a constantly present yet somewhat mild energetic pins and needles sensation that encompasses a person’s entire body. It is usually felt over every square inch of the skin but occasionally manifests itself in the form of a continuously shifting tingling sensation that travels up and down the body in spontaneous waves. However, this effect is reported to be very dose-dependent, as even slight increases in one's dose can result in persisting unpleasant feelings of over-stimulation. | *'''[[Effect::Spontaneous physical sensations]]''' - The "body high" of DOI often described as being notably more intense in comparison to most classical psychedelics such as [[LSD]]. The sensation itself can be described as a constantly present yet somewhat mild energetic pins and needles sensation that encompasses a person’s entire body. It is usually felt over every square inch of the skin but occasionally manifests itself in the form of a continuously shifting tingling sensation that travels up and down the body in spontaneous waves. However, this effect is reported to be very dose-dependent, as even slight increases in one's dose can result in persisting unpleasant feelings of over-stimulation. | ||
*'''[[Effect::Bodily control enhancement]]''' | *'''[[Effect::Bodily control enhancement]]''' | ||
| Line 105: | Line 76: | ||
*'''[[Effect::Transformations]]''' | *'''[[Effect::Transformations]]''' | ||
*'''[[Effect::Internal | *'''[[Effect::Internal hallucination]]''' (''[[effect::autonomous entities]]''; ''[[effect::settings, sceneries, and landscapes]]''; ''[[effect::perspective hallucinations]]'' and ''[[effect::scenarios and plots]]'') - In comparison to other [[psychedelic]]s such as [[LSD]], DOI is extremely high in internal hallucinations. They are more common within dark environments and can be comprehensibly described through its [[Internal_hallucinations#Variations|variations]] as lucid in believability, interactive in style, new experiences in content, autonomous in controllability, [[geometry]]-based in style and almost exclusively of a personal, religious, spiritual, science-fiction, fantasy, surreal, nonsensical or transcendental nature in their overall theme. | ||
*'''[[Effect:: External hallucinations]]''' - These are often present during the comedown and can include [[shadow people]], among other indescribable beings. These external hallucinations are often lucid, interactive, autonomous, and robust. As [[sleep deprivation]] and [[stimulant psychosis]] surface, a [[trip sitter]] should accompany individuals sensitive to stimulants for the last part of the comedown. The visual effects of psychosis have been reported to blend into the psychedelic visuals around the 16-24 hour mark, sometimes accompanied by auditory hallucinations. | *'''[[Effect:: External hallucinations]]''' - These are often present during the comedown and can include [[shadow people]], among other indescribable beings. These external hallucinations are often lucid, interactive, autonomous, and robust. As [[sleep deprivation]] and [[stimulant psychosis]] surface, a [[trip sitter]] should accompany individuals sensitive to stimulants for the last part of the comedown. The visual effects of psychosis have been reported to blend into the psychedelic visuals around the 16-24 hour mark, sometimes accompanied by auditory hallucinations. | ||
| Line 120: | Line 91: | ||
*'''[[Effect::Empathy, affection, and sociability enhancement]]''' - This component is typically manifested only in the context of social settings in which one is within the company of others, and only at lower, non-impairing doses. These feelings of sociability, affection and empathy tend to be weaker and less consistent than those found on substances such as [[MDMA]] and [[2C-B]], but can still prove strong enough to provide long-lasting therapeutic effects. | *'''[[Effect::Empathy, affection, and sociability enhancement]]''' - This component is typically manifested only in the context of social settings in which one is within the company of others, and only at lower, non-impairing doses. These feelings of sociability, affection and empathy tend to be weaker and less consistent than those found on substances such as [[MDMA]] and [[2C-B]], but can still prove strong enough to provide long-lasting therapeutic effects. | ||
*'''[[Effect::Cognitive euphoria]]''' | *'''[[Effect::Cognitive euphoria]]''' | ||
*'''[[Effect:: | *'''[[Effect::Delusion]]''' | ||
*'''[[Effect::Analysis enhancement]]''' - This effect is consistent in its manifestation and [[outrospection]] dominant. | *'''[[Effect::Analysis enhancement]]''' - This effect is consistent in its manifestation and [[outrospection]] dominant. | ||
*'''[[Effect::Emotion enhancement]]''' | *'''[[Effect::Emotion enhancement]]''' | ||
| Line 159: | Line 130: | ||
{{#ask: [[Category:DOI]][[Category:Experience]]|format=ul|Columns=1}} | {{#ask: [[Category:DOI]][[Category:Experience]]|format=ul|Columns=1}} | ||
Additional experience reports can be found here: | Additional experience reports can be found here: | ||
* [https://www.erowid.org/experiences/subs/exp_DOI.shtml Erowid Experience Vaults: DOI] | |||
*[https://www.erowid.org/experiences/subs/exp_DOI.shtml Erowid Experience Vaults: DOI] | |||
==Toxicity and harm potential== | ==Toxicity and harm potential== | ||
| Line 169: | Line 141: | ||
It is strongly recommended that one use [[responsible drug use|harm reduction practices]] when using this substance. | It is strongly recommended that one use [[responsible drug use|harm reduction practices]] when using this substance. | ||
===Overdose=== | |||
{{DOxOD}} | |||
===Tolerance and addiction potential=== | ===Tolerance and addiction potential=== | ||
DOI is [[Addiction potential::not habit-forming]] and the desire to use it can actually decrease with use. It is most often self-regulating. | DOI is [[Addiction potential::not habit-forming]], and the desire to use it can actually decrease with use. It is most often self-regulating. | ||
Tolerance to the effects of DOI | Tolerance to the effects of DOI is built [[Time to full tolerance::almost immediately after ingestion]]. After that, it takes about [[Time to half tolerance::5-7 days]] for the tolerance to be reduced to half and [[Time to zero tolerance::10-14 days]] to be back at baseline (in the absence of further consumption). DOI presents cross-tolerance with [[Cross-tolerance::all [[psychedelic]]s]], meaning that after the consumption of DOI all psychedelics will have a reduced effect. | ||
===Dangerous interactions=== | ===Dangerous interactions=== | ||
{{DangerousInteractions/Intro}} | {{DangerousInteractions/Intro}} | ||
{{DangerousInteractions/Psychedelics}} | |||
==Legal status== | ==Legal status== | ||
*'''Australia''': DOI is not listed as a prohibited substance in The Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP).<ref>{{cite web|title=Poisons Standard 2013|date=July 22, 2013|publisher=Therapeutic Goods Administration|url=http://www.comlaw.gov.au/Details/F2013L01607/229bdf2e-7014-4379-b751-0b584f55d699|id=F2013L01607|isbn=978-1-74241-895-7|type=PDF}}</ref> | |||
*'''Australia | *'''Austria''': DOI is illegal to possess, produce and sell under the NPSG (Neue-Psychoaktive-Substanzen-Gesetz Österreich).{{citation needed}} | ||
*''' | *'''Brazil''': DOI is illegal to possess, produce and sell as it is listed on Portaria SVS/MS nº 344.<ref>{{cite web|title=RESOLUÇÃO DA DIRETORIA COLEGIADA - RDC N° 130, DE 2 DE DEZEMBRO DE 2016|publication-date=December 5, 2016|language=pt|access-date=January 8, 2020|publisher=Agência Nacional de Vigilância Sanitária (Anvisa) [National Sanitary Surveillance Agency]|url=http://portal.anvisa.gov.br/documents/10181/3115436/%281%29RDC_130_2016_.pdf/fc7ea407-3ff5-4fc1-bcfe-2f37504d28b7}}</ref> | ||
*'''Canada | *'''Canada''': DOI is listed as a Schedule 1 drug as it is an analogue of amphetamine.<ref>{{cite web|url=http://isomerdesign.com/Cdsa/schedule.php?schedule=3§ion=ALL&structure=C|title=Schedule III|work=Controlled Drugs and Substances Act (CDSA)|publisher=Isomer Design|access-date=October 10, 2020}}</ref> The CDSA was updated as a result of the Safe Streets Act changing amphetamines from Schedule 3 to Schedule 1. | ||
*'''Denmark | *'''Denmark''': DOI became illegal on April 8, 2007.{{citation needed}} | ||
*'''Latvia | *'''Germany''': DOI is controlled under Anlage II BtMG<ref>{{cite web|url=https://www.gesetze-im-internet.de/btmg_1981/anlage_ii.html|title=Gesetz über den Verkehr mit Betäubungsmitteln: Anlage II|publisher=Bundesamt für Justiz [Federal Office of Justice]|access-date=December 10, 2019|language=de}}</ref> (''Narcotics Act, Schedule II'') as of December 13, 2014.<ref>{{cite web|url=http://www.bgbl.de/xaver/bgbl/start.xav?startbk=Bundesanzeiger_BGBl&jumpTo=bgbl114s1999.pdf|title=Achtundzwanzigste Verordnung zur Änderung betäubungsmittelrechtlicher Vorschriften|publisher=Bundesanzeiger Verlag|work=Bundesgesetzblatt Jahrgang 2014 Teil I Nr. 57|page=1999-2002|publication-date=December 12, 2014|language=de|oclc=231871244|issn=0341-1095|date=December 5, 2014}}</ref> It is illegal to manufacture, possess, import, export, buy, sell, procure or dispense it without a license.<ref>{{cite web|url=https://www.gesetze-im-internet.de/btmg_1981/__29.html|title=Gesetz über den Verkehr mit Betäubungsmitteln: § 29|publisher=Bundesamt für Justiz [Federal Office of Justice]|access-date=December 10, 2019|language=de}}</ref> | ||
*'''Sweden | *'''Latvia''': DOI is a Schedule I controlled substance.<ref>{{cite web|url=http://likumi.lv/doc.php?id=121086|title=Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem|publisher=VSIA Latvijas Vēstnesis|access-date=January 1, 2020|publication-date=November 10, 2005|language=lv}}</ref> | ||
*'''United Kingdom | *'''Sweden''': DOI is a Schedule I substance as of August 30, 2007; this was published by the Medical Products Agency in their regulation LVFS 2007:10.<ref>{{cite web|url=http://www.lakemedelsverket.se/upload/lvfs/LVFS_2007-10.pdf|archive-url=https://web.archive.org/web/20200924055555/https://www.lakemedelsverket.se/upload/lvfs/LVFS_2007-10.pdf|archive-date=August 1, 2019|title=Föreskrifter om ändring i Läkemedelsverkets föreskrifter (LVFS 1997:12) om förteckningar över narkotika|date=August 14, 2007|id=LVFS 2007:10|publication-date=August 30, 2007|issn=1101-5225|publisher=Läkemedelsverket [Medical Products Agency ]|language=sv}}</ref> | ||
*'''United States | *'''Switzerland''': DOI can be considered a controlled substance as a defined derivative of a-Methylphenethylamine under Verzeichnis E point 130. It is legal when used for scientific or industrial use.<ref>{{cite web|url=https://www.admin.ch/opc/de/classified-compilation/20101220/index.html|title=Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien|publisher=Bundeskanzlei [Federal Chancellery of Switzerland]|access-date=January 1, 2020|language=de}}</ref> | ||
**'''Florida | *'''Turkey:''' DOI is a classed as drug and is illegal to possess, produce, supply, or import.<ref>{{cite web|title=Bakanlar Kurulu Kararı - Karar Sayısı : 2013/5742|url=https://resmigazete.gov.tr/eskiler/2014/01/20140125-3.htm|publisher=Başbakanlık Mevzuatı Geliştirme ve Yayın Genel Müdürlüğü [General Directorate of Legislation Development and Publication]|publication-date=January 25, 2014|date=December 16, 2013|language=tr}}</ref><ref>{{cite web|title=Kararnamenin Eki: Liste|url=https://resmigazete.gov.tr/eskiler/2014/01/20140125-3-1.pdf|publisher=Başbakanlık Mevzuatı Geliştirme ve Yayın Genel Müdürlüğü [General Directorate of Legislation Development and Publication]|publication-date=January 25, 2014|date=December 16, 2013|language=tr|id=2013/5742|work=Resmî Gazete, Sayı: 28893}}</ref> | ||
*'''United Kingdom''': DOI is illegal to produce, supply, or import under the Psychoactive Substance Act, which came into effect on May 26th, 2016.<ref>{{cite web|url=http://www.legislation.gov.uk/ukpga/2016/2/contents/enacted|title=Psychoactive Substances Act 2016|access-date=January 1, 2020|publisher=UK Government}}</ref> | |||
*'''United States''': DOI is not scheduled in the United States, but it is likely that it would be considered an analog (of DOB) in which case sales or possession could be prosecuted under the Federal Analogue Act. DOI is regularly used in animal and in vitro research.{{citation needed}} | |||
**'''Florida''': DOI is a Schedule I controlled substance in the state of Florida.<ref>{{cite web|title=The 2015 Florida Statutes - Chapter 893|url=http://leg.state.fl.us/statutes/index.cfm?App_mode=Display_Statute&URL=0800-0899/0893/0893.html|publisher=The Florida Legislature|access-date=July 18, 2020}}</ref> | |||
==See also== | ==See also== | ||
*[[Responsible use]] | *[[Responsible use]] | ||
| Line 205: | Line 180: | ||
*[https://erowid.org/chemicals/doi/doi.shtml DOI (Erowid Vault)] | *[https://erowid.org/chemicals/doi/doi.shtml DOI (Erowid Vault)] | ||
*[http://isomerdesign.com/PiHKAL/read.php?domain=pk&id=67 DOI (PiHKAL / Isomer Design)] | *[http://isomerdesign.com/PiHKAL/read.php?domain=pk&id=67 DOI (PiHKAL / Isomer Design)] | ||
===Discussion=== | ===Discussion=== | ||
*[http://www.bluelight.org/vb/threads/224091-The-Big-and-Dandy-DOI-Thread The Big & Dandy DOI Thread (Bluelight)] | *[http://www.bluelight.org/vb/threads/224091-The-Big-and-Dandy-DOI-Thread The Big & Dandy DOI Thread (Bluelight)] | ||
| Line 211: | Line 187: | ||
{{reflist|2}} | {{reflist|2}} | ||
[[Category: | [[Category:Psychoactive substance]] | ||
[[Category:Psychedelic]] | [[Category:Psychedelic]] | ||
[[Category: | [[Category:DOx]] | ||
{{#set:Featured=true}} | |||